| Non-Small Cell Lung Carcinoma

Krazati vs Yervoy

Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.

Deep comparison between: Krazati vs Yervoy with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsYervoy has a higher rate of injection site reactions vs Krazati based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Yervoy but not Krazati, including UnitedHealthcare

Category

Krazati

Yervoy

At A Glance

RouteOral

FrequencyTwice daily

ClassKRAS G12C inhibitor

RouteIV infusion

FrequencyEvery 3 weeks (monotherapy) or every 6 weeks (combination)

ClassCTLA-4 antagonist

Indications

Non-Small Cell Lung Carcinoma
Colorectal Neoplasms

melanoma
Renal Cell Carcinoma
Colorectal Carcinoma
Liver carcinoma
Non-Small Cell Lung Carcinoma
Malignant Pleural Mesothelioma
Squamous cell carcinoma of esophagus

Dosing

Non-Small Cell Lung Carcinoma 600 mg orally twice daily as a single agent until disease progression or unacceptable toxicity; swallow tablets whole with or without food.

Colorectal Neoplasms 600 mg orally twice daily in combination with cetuximab until disease progression or unacceptable toxicity; swallow tablets whole with or without food.

Melanoma (unresectable or metastatic) 3 mg/kg IV every 3 weeks for 4 doses, or 3 mg/kg IV with nivolumab 1 mg/kg IV every 3 weeks for 4 doses followed by nivolumab monotherapy

Melanoma (adjuvant) 3 mg/kg IV every 3 weeks for 4 doses, then 3 mg/kg every 12 weeks for up to 4 additional doses

Renal Cell Carcinoma 1 mg/kg IV with nivolumab 3 mg/kg IV every 3 weeks for 4 doses, followed by nivolumab monotherapy

Colorectal Carcinoma 1 mg/kg IV with nivolumab 240 mg or 3 mg/kg IV (weight-based) every 3 weeks for 4 doses, followed by nivolumab monotherapy

Liver carcinoma 3 mg/kg IV with nivolumab 1 mg/kg IV every 3 weeks for up to 4 doses, followed by nivolumab monotherapy

Non-Small Cell Lung Carcinoma 1 mg/kg IV every 6 weeks with nivolumab 360 mg every 3 weeks, or with nivolumab and 2 cycles of platinum-doublet chemotherapy

Malignant Pleural Mesothelioma 1 mg/kg IV every 6 weeks with nivolumab 360 mg every 3 weeks

Squamous cell carcinoma of esophagus 1 mg/kg IV every 6 weeks with nivolumab 3 mg/kg every 2 weeks or 360 mg every 3 weeks

Contraindications

—

Drug Interactions

663View drug interactions

676View drug interactions

Adverse Reactions

Most common (>=25%) nausea, diarrhea, vomiting, fatigue, musculoskeletal pain, hepatotoxicity, renal impairment, edema, dyspnea, decreased appetite

Serious pneumonia, dyspnea, renal impairment, sepsis, respiratory failure, pleural effusion, anemia, cardiac failure

Most common (>=20%) fatigue, diarrhea, rash, pruritus, nausea, pyrexia, musculoskeletal pain, decreased appetite, cough, headache, dyspnea, vomiting, abdominal pain, arthralgia

Serious immune-mediated colitis, hepatitis, pneumonitis, endocrinopathies, nephritis, dermatologic reactions, neurological toxicities, myocarditis, adrenal insufficiency, hypophysitis, hyperthyroidism, hypothyroidism

Pharmacology

Adagrasib is an irreversible KRAS G12C inhibitor that covalently binds to the mutant cysteine residue, locking KRAS G12C in its inactive GDP-bound state and preventing downstream signaling without affecting wild-type KRAS.

Ipilimumab blocks CTLA-4, a negative regulator of T-cell activity, thereby augmenting T-cell activation and proliferation including tumor-infiltrating T-effector cells and reducing T-regulatory cell function.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Krazati